Working together to prevent blindness
Odylia Therapeutics is a 501(c)(3) corporation combining the expertise and experience of our founders, board members, and partner organizations to fill a unique void in moving ultra-rare inherited retinal diseases from science to humans. Our organization focuses on those diseases that would typically have limited commercial appeal and would be neglected, even though the science is available to make significant progress.
Board of Directors
Luk Vandenberghe, Ph.D.
Associate Professor, Harvard Medical School
Director, Grousbeck Gene Therapy Center
Massachusetts Eye and Ear
Scott Dorfman, B.B.A.
CEO, Odylia Therapeutics
Matthew Pletcher, Ph.D.
RDH12 Fund for Sight
Emil Kakkis, M.D., Ph.D.
President and Founder
Ultragenyx Pharmaceutical Inc
Board of Advisors
Eric Pierce, M.D., Ph.D.
Director, Ocular Genomics Institute
Harvard Medical School
Director, Inherited Retinal Disorders Services
Massachusetts Eye and Ear
Joy Cavagnaro, Ph.D.
President, Access Bio
Jean Bennett, M.D., Ph.D.
Professor, Perelman School of Medicine
University of Pennsylvania
Alberto Auricchio, Ph.D.
Associate Professor of Medical Genetics
“Federico II” University Napoli
Principal Investigator, TIGEM
Alan Spiro, B.A., Ph.D., J.D.
Partner, ExSight Ventures
Founding Members
Luk Vandenberghe
Eric Pierce
Scott Dorfman
John Fernandez, M.S.
President and CEO,
Massachusetts Eye and Ear
Joan Miller, M.D.
Chief of Ophthalmology,
Massachusetts Eye and Ear
Associates
Ashley Winslow, Ph.D
Chief Scientific Officer,
Odylia Therapeutics
Lara Aronoff Dorfman, MSW
Director of Business Development,
Odylia Therapeutics
Susie Trotochaud, A.B.J., M.B.A.
Volunteer Marketing Support,
Odylia Therapeutics